Table 1. Demographics and baseline characteristics.
| Japan ITT patients (n = 155) | Japan extension study patients | ||
|---|---|---|---|
| EBID→EQW | EQW | ||
| (n = 62) | (n = 74) | ||
| Age (years) | 61 (9) | 60 (9) | 61 (10) |
| Male, n (%) | 91 (59) | 38 (61) | 43 (58) |
| HbA1c (%) | 8.8 (0.9) | 8.8 (1.0) | 8.8 (1.0) |
| Duration of diabetes (years) | 10 (7) | 11 (7) | 10 (6) |
| FSG (mg/dL) | 166 (41) | 168 (41) | 167 (43) |
| Bodyweight (kg) | 69 (13) | 71 (13) | 68 (13) |
| BMI (kg/m2) | 26 (4) | 27 (4) | 26 (3) |
| Background OAM, n (%) | |||
| SU | 35 (23) | 11 (18) | 19 (26) |
| SU + MET | 79 (51) | 34 (55) | 37 (50) |
| SU + TZD | 18 (12) | 10 (16) | 6 (8) |
| MET | 19 (12) | 6 (10) | 10 (14) |
| MET + TZD | 2 (1) | 0 (0) | 1 (1) |
| TZD | 2 (1) | 1 (2) | 1 (1) |
Data are presented as mean (standard deviation), unless otherwise noted. BMI, body mass index; EBID, exenatide twice daily; EQW, exenatide once weekly; FSG, fasting serum glucose; HbA1c, glycated hemoglobin; ITT, intent‐to‐treat; MET, metformin; OAM, oral antidiabetes medication; SU, sulfonylurea; TZD, thiazolidinedione.